Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | ETV6 | P41212 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1093041 | 0.87 | GPR119 (0.56) | GPR119CYP4F2CYP4A11KDM4ENPC1 | |
| SCHEMBL10067601 | 0.80 | GPR119 (0.42) | GPR119CYP4F2CYP4A11KDM4ENPC1 | |
| SCHEMBL904059 | 0.80 | GPR119 (0.42) | GPR119CYP4F2CYP4A11KDM4ENPC1 | |
| SCHEMBL904048 | 0.78 | GPR119 (0.46) | GPR119KDM4ENPC1RAB9A | |
| SCHEMBL1091938 | 0.76 | GPR119 (0.50) | GPR119CYP4F2CYP4A11KDM4ENPC1 | |
| SCHEMBL903971 | 0.75 | CHRNA3 (0.47) | GPR119 | |
| SCHEMBL10067420 | 0.74 | GPR119 (0.47) | GPR119 | |
| SCHEMBL1092523 | 0.74 | GPR119 (0.53) | GPR119CYP4F2CYP4A11KDM4ENPC1 | |
| SCHEMBL904119 | 0.74 | GPR119 (0.47) | GPR119 | |
| SCHEMBL904090 | 0.73 | GPR119 (0.41) | GPR119KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012041158-A1 | TRICYCLIC COMPOUND, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | 上海恒瑞医药有限公司 (CN) | 2012-04-05 | — | — | WO | disclosed |